全文获取类型
收费全文 | 27817篇 |
免费 | 2410篇 |
国内免费 | 1670篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 396篇 |
妇产科学 | 101篇 |
基础医学 | 3588篇 |
口腔科学 | 82篇 |
临床医学 | 2474篇 |
内科学 | 12476篇 |
皮肤病学 | 123篇 |
神经病学 | 91篇 |
特种医学 | 498篇 |
外国民族医学 | 4篇 |
外科学 | 951篇 |
综合类 | 5318篇 |
现状与发展 | 11篇 |
预防医学 | 2055篇 |
眼科学 | 12篇 |
药学 | 2045篇 |
9篇 | |
中国医学 | 1181篇 |
肿瘤学 | 474篇 |
出版年
2024年 | 31篇 |
2023年 | 344篇 |
2022年 | 599篇 |
2021年 | 755篇 |
2020年 | 806篇 |
2019年 | 947篇 |
2018年 | 847篇 |
2017年 | 930篇 |
2016年 | 1115篇 |
2015年 | 1135篇 |
2014年 | 1760篇 |
2013年 | 1848篇 |
2012年 | 1659篇 |
2011年 | 1970篇 |
2010年 | 1459篇 |
2009年 | 1328篇 |
2008年 | 1368篇 |
2007年 | 1487篇 |
2006年 | 1452篇 |
2005年 | 1178篇 |
2004年 | 1025篇 |
2003年 | 915篇 |
2002年 | 844篇 |
2001年 | 848篇 |
2000年 | 702篇 |
1999年 | 549篇 |
1998年 | 490篇 |
1997年 | 463篇 |
1996年 | 424篇 |
1995年 | 414篇 |
1994年 | 352篇 |
1993年 | 300篇 |
1992年 | 265篇 |
1991年 | 191篇 |
1990年 | 157篇 |
1989年 | 126篇 |
1988年 | 138篇 |
1987年 | 113篇 |
1986年 | 87篇 |
1985年 | 94篇 |
1984年 | 79篇 |
1983年 | 50篇 |
1982年 | 54篇 |
1981年 | 46篇 |
1980年 | 47篇 |
1979年 | 27篇 |
1978年 | 34篇 |
1977年 | 20篇 |
1974年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
2.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
3.
4.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
5.
6.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
7.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
8.
MASAFUMI IKEDA SHIGETOSHI FUJIYAMA MOTOHIKO TANAKA MICHIO SATA TATSUYA IDE HIROSHI YATSUHASHI HIROSHI WATANABE 《Journal of gastroenterology and hepatology》2006,21(1):122-128
Background and Aim: This study investigated the clinical features of hepatocellular carcinoma in patients with sustained virological response to interferon for hepatitis C viral (HCV) infection. Methods: A total of 7715 patients with HCV infection were treated with interferon and followed up for more than 1 year after withdrawal of interferon in 64 Japanese hospitals and clinics between July 1988 and August 2001. Sustained virological response was obtained in 2515 (32.6%) patients. Of these 2515 patients, clinical data were collected for 38 patients in whom hepatocellular carcinoma developed. Sustained virological response was defined as HCV RNA negativity more than 6 months after the termination of interferon. Results: All patients were HCV RNA negative at the time of diagnosis of hepatocellular carcinoma. The median period until the detection of hepatocellular carcinoma was 4.7 years (range 1.4–9.0 years). There were significant improvements in hepatic function including serum albumin, aspartate aminotransferase, alanine aminotransferase, indocyanine green test, platelet count and histological activity grade in comparison with those before interferon therapy and at the onset of hepatocellular carcinoma. The maximum tumor size in patients without medical follow‐up for 1 year or more (median: 60 mm) was significantly larger than in patients who were periodically followed up for 6 months or less (median: 25 mm) (P = 0.002). Conclusions: The present findings emphasize the importance of regular medical follow up of patients with HCV infection, as even patients showing a sustained virological response to interferon and in whom hepatic function has improved have the potential to develop hepatocellular carcinoma. 相似文献
9.
10.
目的探讨复方丹参注射液联合干扰素治疗慢性乙肝患者的疗效。方法110例慢性乙肝患者,按随机方法分成①对照组30例,应用普通保肝药物治疗,疗程6个月;②丹参组30例,应用复方丹参注射液(每ml含丹参、降香各1g)30ml加入10%葡萄糖溶液300ml中静脉注射1个月;③IFN组30例,应用IFN—α 3MU,隔日一次肌内注射,3个月;④联合组20例,应用复方丹参注射液30ml加10%葡萄糖溶液300ml静脉注射1个月,IFN-α 3MU,隔日一次肌内注射,3个月。丹参组,IFN组和联合组保肝药物治疗同对照组。四组病例在性别、年龄、病程,治疗前肝功能等方面均无统计学差异。治疗前检测肝功能,肝炎病毒标志,血清HA、IV—C、PCI—Ⅱ,部分病例进行肝穿病理检查。治疗开始后每月检测肝功能,3个月(治疗后)和6个月(随访时)时检测血清HA、IV—C、PCⅢ及乙肝病毒标志,治疗后1年行肝穿病理检查。结果治疗前四组患者血清HA、PCⅢ、IV—C水平无统计学差异;治疗后丹参组、IFN组、联合组血清HA、FCⅢ、IV—C水平较治疗前及对照组有不同程度的降低。结论复方丹参注射液联合IFN治疗可使血清HA、PCⅢ、IV—C有明显下降,肝组织病理改变明显改善,为目前有效的慢性乙肝治疗措施。 相似文献